TY - JOUR T1 - Secondary infections modify the overall course of hospitalized COVID-19 patients: A retrospective study from a network of hospitals across North India JF - medRxiv DO - 10.1101/2021.09.27.21264070 SP - 2021.09.27.21264070 AU - Sandeep Budhiraja AU - Bansidhar Tarai AU - Dinesh Jain AU - Mona Aggarwal AU - Abhaya Indrayan AU - Poonam Das AU - RS Mishra AU - Supriya Bali AU - Monica Mahajan AU - Jay Kirtani AU - Rommel Tickoo AU - Pankaj Soni AU - Vivek Nangia AU - Ajay Lall AU - Nevin Kishore AU - Ashish Jain AU - Omender Singh AU - Namrita Singh AU - Ashok Kumar AU - Prashant Saxena AU - Arun Dewan AU - Ritesh Aggarwal AU - Mukesh Mehra AU - Meenakshi Jain AU - Vimal Nakra AU - B D Sharma AU - Praveen Kumar Pandey AU - YP Singh AU - Vijay Arora AU - Suchitra Jain AU - Ranjana Chhabra AU - Preeti Tuli AU - Vandana Boobna AU - Alok Joshi AU - Manoj Aggarwal AU - Rajiv Gupta AU - Pankaj Aneja AU - Sanjay Dhall AU - Vineet Arora AU - Inder Mohan Chugh AU - Sandeep Garg AU - Vikas Mittal AU - Ajay Gupta AU - Bikram Jyoti AU - Puneet Sharma AU - Pooja Bhasin AU - Shakti Jain AU - RK Singhal AU - Atul Bhasin AU - Anil Vardani AU - Vivek Pal AU - Deepak Gargi Pande AU - Tribhuvan Gulati AU - Sandeep Nayar AU - Sunny Kalra AU - Manish Garg AU - Rajesh Pande AU - Pradyut Bag AU - Arpit Gupta AU - Jitin Sharma AU - Anil Handoo AU - Purabi Burman AU - Ajay Kumar Gupta AU - Pankaj Nand Choudhary AU - Ashish Gupta AU - Puneet Gupta AU - Sharad Joshi AU - Nitesh Tayal AU - Manish Gupta AU - Anita Khanna AU - Sachin Kishore AU - Shailesh Sahay AU - Rajiv Dang AU - Neelima Mishra AU - Sunil Sekhri AU - Rajneesh Chandra Srivastava AU - Mitali Bharat Agrawal AU - Mohit Mathur AU - Akash Banwari AU - Sumit Khetarpal AU - Sachin Pandove AU - Deepak Bhasin AU - Harpal Singh AU - Devender Midha AU - Anjali Bhutani AU - Manpreet Kaur AU - Amarjit Singh AU - Shalini Sharma AU - Komal Singla AU - Pooja Gupta AU - Vinay Sagar AU - Ambrish Dixit AU - Rashmi Bajpai AU - Vaibhav Chachra AU - Puneet Tyagi AU - Sanjay Saxena AU - Bhupesh Uniyal AU - Shantanu Belwal AU - Imliwati Aier AU - Mini Singhal AU - Ankit Khaduri Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264070.abstract N2 - Introduction SARS-CoV-2 infection increases the risk of secondary bacterial and fungal infections and contributes to adverse outcomes. The present study was undertaken to get better insights into the extent of secondary bacterial and fungal infections in Indian hospitalized patients and to assess how these alter the course of COVID-19 so that the control measures can be suggested.Methods This is a retrospective, multicentre study where data of all RT-PCR positive COVID-19 patients was accessed from Electronic Health Records (EHR) of a network of 10 hospitals across 5 North Indian states, admitted during the period from March 2020 to July 2021.The data included demographic profile of patients, clinical characteristics, laboratory parameters, treatment modalities, and outcome in those with secondary infections (SIs) and those without SIs. Spectrum of SIS was also studied in detail.Results Of 19852 RT-PCR positive SARS-CO2 patients admitted during the study period, 1940 (9.8%) patients developed SIs. Patients with SIs were 8 years older on average (median age 62.6 years versus 54.3 years; P<0.001) than those without SIs. The risk of SIs was significantly (p < 0.001) associated with age, severity of disease at admission, diabetes, ICU admission, and ventilator use.The most common site of infection was urinary tract infection (UTI) (41.7%), followed by blood stream infection (BSI) (30.8%), sputum/BAL/ET fluid (24.8%), and the least was pus/wound discharge (2.6%). As many as 13.4% had infections with more than organism and 34.1% patients had positive cultures from more than one site. Gram negative bacilli (GNB) were the commonest organisms (63.2%), followed by Gram positive cocci (GPC) (19.6%) and fungus (17.3%). Most of the patients with SIs were on multiple antimicrobials – the most commonly used were the BL-BLI for GNBs (76.9%) followed by carbapenems (57.7%), cephalosporins (53.9%) and antibiotics carbapenem resistant entreobacteriace (47.1%). The usage of emperical antibiotics for GPCs was in 58.9% and of antifungals in 56.9% of cases, and substantially more than the results obtained by culture.The average stay in hospital for patients with SIs was twice than those without SIs (median 13 days versus 7 days). The overall mortality in the group with SIs (40.3%) was more than 8 times of that in those without SIs (4.6%). Only 1.2% of SI patients with mild COVID-19 at presentation died, while 17.5% of those with moderate disease and 58.5% of those with severe COVID-19 died (P< 0.001). The mortality was highest in those with BSI (49.8%), closely followed by those with HAP (47.9%), and then UTI and SSTI (29.4% each). The mortality rate where only one microorganism was identified was 37.8% and rose to 56.3% in those with more than one microorganism. The mortality in cases with only one site of infection was 28.8%, which steeply rose to 62.5% in cases with multiple sites of infection. The mortality in diabetic patients with SIs was 45.2% while in non-diabetics it was 34.3% (p < 0.001).Conclusions Secondary bacterial and fungal infections can complicate the course of almost 10% of COVID-19 hospitalised patients. These patients tend to not only have a much longer stay in hospital, but also a higher requirement for oxygen and ICU care. The mortality in this group rises steeply by as much as 8 times. The group most vulnerable to this complication are those with more severe COVID-19 illness, elderly, and diabetic patients. Varying results in different studies suggest that a region or country specific guideline be developed for appropriate use of antibiotics and antifungals to prevent their overuse in such cases. Judicious empiric use of combination antimicrobials in this set of vulnerable COVID-19 patients can save lives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding has been included in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee, Max Super Speciality Hospital (A unit of Devki Devi Foundation), Address: Service Floor, Office of Ethics Committee, East Block, next to Conference Room, Max Super Speciality Hospital, Saket (A unit of Devki Devi Foundation), 2, Press Enclave Road, Saket, New Delhi 110017 vide ref. no. BHR/RS/MSSH/DDF/SKT-2/IEC/IM/21-24 dated 7th September 2021. The IEC provided no objection and approved the publication of this manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata of all RTPCR positive COVID19 patients was accessed from Electronic Health Records (EHR) of a network of 10 hospitals across 5 North Indian states, admitted during the period from March 2020 to July 2021. ER -